Biomarker for Prostate Cancer
AssigneeThe Johns Hopkins University
InventorsZhen Zhang, Daniel W. Chan, Carolyn N. Rosenzwelg
Life of this patent
Estimating the term…
Abstract
The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass spectrometry.
Claims23
A method for qualifying prostate cancer status in a subject comprising:
- (a) measuring the PCI biomarker in a biological sample from the subject;
- and
- (b) correlating the measurement with prostate cancer status.
A method of determining the probability of prostate cancer recurrence comprising:
- (a) measuring the PCI and C4a biomarkers in a biological sample from the subject;
- and
- (b) correlating the measurement with prostate cancer recurrence.
6-9. (canceled)
11-15. (canceled)
(canceled)
A composition comprising a purified PCI.
A composition comprising a biospecific capture reagent that specifically binds PCI.
19-20. (canceled)
(canceled)
A kit comprising:
- (a) a solid support comprising at least one capture reagent attached thereto, wherein the capture reagent binds to PCI;
- and
- (b) instructions for using the solid support to detect PCI.
23-30. (canceled)
-33. (canceled)
(canceled)
(canceled)
A method of treating a condition in a subject, wherein said method comprises:
- administering to a subject a therapeutically effective amount of a small molecule, wherein said small molecule inhibits expression of PCI.
Dependencies are inferred from the claim text.